

- the first part of the second antigen binding domain capable of specific binding to a first target is fused either directly or via a first peptide linker to the N-terminus of the spacer domain,

- the second part of the second antigen binding domain capable of specific binding to a first target is fused either directly or via a second peptide linker to the C-terminus of the spacer domain, and

- the second part of an antigen binding domain capable of specific binding to a second target is fused either directly or via a third peptide linker to the C-terminus of the second part of the second antigen binding domain capable of specific binding to a first target or is fused either directly or via a third peptide linker to the N-terminus of the first part of the second antigen binding domain capable of specific binding to a first target,

wherein the first part and the second part of the antigen binding domain capable of specific binding to the second target are associated with each other to form the antigen binding domain capable of specific binding to the second target and wherein the first part and the second part of the first and second antigen binding domain capable of specific binding to the first target are associated with each other to form a circular fusion polypeptide, and wherein the spacer domain of the first fusion polypeptide and the spacer domain of the second fusion polypeptide are associated covalently to each other by a disulfide bond and comprise modifications promoting the association of the first and second fusion polypeptide.

In one aspect, the present disclosure provides a bispecific antibody consisting of two fusion polypeptides and comprising two antigen binding domains capable of specific binding to a first target and one antigen binding domain capable of specific binding to a second target comprising

- (a) a first fusion polypeptide comprising ~~a first part of a first antigen binding domain~~ antibody heavy chain Fab fragment (VH-CH1) capable of specific binding to the first target, a spacer domain, ~~a second part of a first antigen binding domain~~ antibody light chain Fab fragment (VL-Ckappa) capable of specific binding to the first target and ~~a first part of an antigen binding domain~~ antibody cross-Fab fragment comprising VH-Ckappa capable of specific binding to the second target, wherein
- the spacer domain comprises an antibody hinge region or a fragment thereof and an IgG1 Fc domain ~~is a polypeptide and comprises at least 25 amino acid residues,~~
 - the ~~first part of the first antigen binding domain~~ antibody heavy chain Fab fragment (VH-CH1) capable of specific binding to the first target is fused via a first peptide linker to the N-terminus of the spacer domain,

- the ~~second part of the first antigen-binding domain~~antibody light chain Fab fragment (VL-Ckappa) capable of specific binding to the first target is fused via a second peptide linker to the C-terminus of the spacer domain, and

- the ~~first part of an antigen-binding domain~~antibody cross-Fab fragment comprising VH-Ckappa capable of specific binding to a second target is fused via a third peptide linker to the C-terminus of the ~~second part of the first antigen-binding domain~~antibody light chain Fab fragment (VL-Ckappa) capable of specific binding to the first target or is fused via a third peptide linker to the N-terminus of the ~~first part of the first antigen-binding domain~~antibody heavy chain Fab fragment (VH-CH1) capable of specific binding to the first target, and

(b) a second fusion polypeptide comprising a ~~first part of a second antigen-binding domain~~second antibody heavy chain Fab fragment (VH-CH1) capable of specific binding to a first target, a spacer domain, a second ~~part of the second antigen-binding domain~~antibody light chain Fab fragment (VL-Ckappa) capable of specific binding to a first target and the ~~second part of an antigen-binding domain~~an antibody cross-Fab fragment comprising VL-CH1 capable of specific binding to a second target, wherein

- the spacer domain comprises an antibody hinge region or a fragment thereof and an IgG1 Fc domain~~is a polypeptide and comprises at least 25 amino acid residues,~~

- the ~~first part of the second antigen-binding domain~~second antibody heavy chain Fab fragment (VH-CH1) capable of specific binding to a first target is fused via a first peptide linker to the N-terminus of the spacer domain,

- the ~~second part of the second antigen-binding domain~~antibody light chain Fab fragment (VL-Ckappa) capable of specific binding to a first target is fused via a second peptide linker to the C-terminus of the spacer domain, and

- the ~~second part of an antigen-binding domain~~antibody cross-Fab fragment comprising VL-CH1 capable of specific binding to a second target is fused via a third peptide linker to the C-terminus of the second ~~part of the second antigen-binding domain~~antibody light chain Fab fragment (VL-Ckappa) capable of specific binding to a first target or is fused via a third peptide linker to the N-terminus of the ~~first part of the second antigen-binding domain~~second antibody heavy chain Fab fragment (VH-CH1) capable of specific binding to a first target,

and wherein the ~~first part and the second part of the antigen binding domain~~ antibody cross-Fab fragment comprising VH-Ckappa and the antibody cross-Fab fragment comprising VL-CH1 capable of specific binding to the second target are associated with each other to form the antigen binding domain capable of specific binding to the second target and wherein the ~~first part~~ antibody heavy chain Fab fragment (VH-CH1) and the ~~second part~~ antibody light chain Fab fragment (VL-Ckappa) of the first and second antigen binding domain capable of specific binding to the first target are associated with each other to form a circular fusion polypeptide, and

wherein the spacer domain of the first fusion polypeptide and the spacer domain of the second fusion polypeptide are associated covalently to each other by a disulfide bond and comprise knob-into-hole modifications promoting the association of the first and second fusion polypeptide ~~the spacer domain of the first fusion polypeptide and the spacer domain of the second fusion polypeptide are associated covalently to each other by a disulfide bond and comprise modifications promoting the association of the first and second fusion polypeptide, and wherein the spacer domain of the first fusion polypeptide comprises holes and the spacer domain of the second fusion polypeptide comprises knobs according to the knobs into hole method.~~

In one example, provided is a bispecific antibody as defined herein before, wherein in the first fusion polypeptide the first part of an antigen binding domain capable of specific binding to a second target is fused either directly or via a third peptide linker to the C-terminus of the second part of the first antigen binding domain capable of specific binding to the first target and wherein in the second fusion polypeptide the second part of an antigen binding domain capable of specific binding to a second target is fused either directly or via a third peptide linker to the C-terminus of the second part of the first antigen binding domain capable of specific binding to the first target.

In another example, provided is a bispecific antibody as defined herein before, wherein in the first fusion polypeptide the first part of an antigen binding domain capable of specific binding to a second target is fused either directly or via a third peptide linker to the N-terminus of the first part of the first antigen binding domain capable of specific binding to the first target and wherein in the second fusion polypeptide the second part of an antigen binding domain capable of specific binding to a second target is fused either directly or via a third peptide linker to the N-

Claims

1. A bispecific antibody consisting of two fusion polypeptides and comprising two antigen binding domains capable of specific binding to a first target and one antigen binding domain capable of specific binding to a second target comprising

- (a) a first fusion polypeptide comprising ~~a first part of a first antigen-binding domain~~ antibody heavy chain Fab fragment (VH-CH1) capable of specific binding to the first target, a spacer domain, ~~a second part of a first antigen-binding domain~~ an antibody light chain Fab fragment (VL-Ckappa) capable of specific binding to the first target and ~~a first part of an antigen-binding domain~~ an antibody cross-Fab fragment comprising VH-Ckappa capable of specific binding to the second target, wherein
 - the spacer domain ~~is a polypeptide and comprises at least 25 amino acid residues~~ comprises an antibody hinge region or a fragment thereof and an IgG1 Fc domain,
 - the ~~first part of the first antigen-binding domain~~ antibody heavy chain Fab fragment (VH-CH1) capable of specific binding to the first target is fused via a first peptide linker to the N-terminus of the spacer domain,
 - the ~~second part of the first antigen-binding domain~~ antibody light chain Fab fragment (VL-Ckappa) capable of specific binding to the first target is fused via a second peptide linker to the C-terminus of the spacer domain, and
 - the ~~first part of an antigen-binding domain~~ antibody cross-Fab fragment comprising VH-Ckappa capable of specific binding to a second target is fused via a third peptide linker to the C-terminus of the ~~second part of the first antigen-binding domain~~ antibody light chain Fab fragment (VL-Ckappa) capable of specific binding to the first target or is fused via a third peptide linker to the N-terminus of the ~~first part of the first antigen-binding domain~~ antibody heavy chain Fab fragment (VH-CH1) capable of specific binding to the first target, and
- (b) a second fusion polypeptide comprising a ~~first part of a second antigen-binding domain~~ second antibody heavy chain Fab fragment (VH-CH1) capable of specific binding to a first target, a spacer domain, a second ~~part of the second antigen-binding domain~~ antibody light chain Fab fragment (VL-Ckappa) capable of specific binding to a first target and ~~the second part of an antigen-binding domain~~ an antibody cross-Fab fragment comprising VL-CH1 capable of specific binding to a second target, wherein

- the spacer domain ~~is a polypeptide and comprises at least 25 amino acid residues~~comprises an antibody hinge region or a fragment thereof and an IgG1 Fc domain,
- the ~~first part of the second antigen-binding domain~~second antibody heavy chain Fab fragment (VH-CH1) capable of specific binding to a first target is fused via a first peptide linker to the N-terminus of the spacer domain,
- the second ~~part of the second antigen-binding domain~~antibody light chain Fab fragment (VL-Ckappa) capable of specific binding to a first target is fused via a second peptide linker to the C-terminus of the spacer domain, and
- the ~~second part of an antigen-binding domain~~antibody cross-Fab fragment comprising VL-CH1 capable of specific binding to a second target is fused via a third peptide linker to the C-terminus of the second ~~part of the second antigen-binding domain~~antibody light chain Fab fragment (VL-Ckappa) capable of specific binding to a first target or is fused via a third peptide linker to the N-terminus of the ~~first part of the second antigen-binding domain~~second antibody heavy chain Fab fragment (VH-CH1) capable of specific binding to a first target,

and wherein the ~~first part and the second part of the antigen-binding domain~~antibody cross-Fab fragment comprising VH-Ckappa and the antibody cross-Fab fragment comprising VL-CH1 capable of specific binding to the second target are associated with each other to form the antigen binding domain capable of specific binding to the second target and wherein the ~~first part~~antibody heavy chain Fab fragment (VH-CH1) and the ~~second part~~antibody light chain Fab fragment (VL-Ckappa) of the first and second antigen binding domain capable of specific binding to the first target are associated with each other to form a circular fusion polypeptide, and

wherein ~~the spacer domain of the first fusion polypeptide and the spacer domain of the second fusion polypeptide are associated covalently to each other by a disulfide bond and comprise knob-into-hole modifications promoting the association of the first and second fusion polypeptide~~the spacer domain of the first fusion polypeptide and the spacer domain of the second fusion polypeptide are associated covalently to each other by a disulfide bond and comprise modifications promoting the association of the first and second fusion polypeptide, and wherein the spacer domain of the first fusion polypeptide comprises holes and the spacer domain of the second fusion polypeptide comprises knobs according to the knobs into hole method.

2. —The bispecific antibody of claim 1, wherein in the first fusion polypeptide the first part of an antigen-binding domain capable of specific binding to a second target is fused via a third

peptide linker to the C-terminus of the second part of the first antigen binding domain capable of specific binding to the first target and wherein in the second fusion polypeptide the second part of an antigen binding domain capable of specific binding to a second target is fused via a third peptide linker to the C-terminus of the second part of the first antigen binding domain capable of specific binding to the first target.

32. The bispecific antibody of ~~claims 1 or 2~~claim 1, wherein the third peptide linker connecting the antibody cross-Fab fragment comprising VH-Ckappa or the antibody cross-Fab fragment comprising VL-CH1 first part or the second part of an antigen binding domain capable of specific binding to a second target comprises at least 15 amino acids.

4. ~~The bispecific antibody of any one of claims 1 to 3, wherein the first fusion polypeptide comprises the heavy chain variable domain of the antigen binding domain capable of specific binding to a second target and the second fusion polypeptide comprises the antibody light chain variable domain of the antigen binding domain capable of specific binding to a second target or vice versa.~~

5. ~~The bispecific antibody of any one of claims 1 to 4, wherein in both the first fusion polypeptide and the second fusion polypeptide the first part of the antigen binding domain capable of specific binding to the first target is an antibody heavy chain Fab fragment and the second part of the antigen binding domain capable of specific binding to the first target is an antibody light chain Fab fragment.~~

6. ~~The bispecific antibody of any one of claims 1 to 5, wherein the spacer domain comprises an antibody hinge region or a fragment thereof, an antibody CH2 domain, and an antibody CH3 domain or a fragment thereof.~~

7. ~~The bispecific antibody of any one of claims 1 to 6, wherein the spacer domain comprises an antibody hinge region or a fragment thereof and an IgG1 Fc domain.~~

83. The bispecific antibody of ~~claim 7~~claims 1 or 2, wherein the IgG1 Fc domain comprises amino acid substitutions L234A, L235A and P329G (numbering according to Kabat EU index).

94. The bispecific antibody of any one of claims 1 to 83, wherein the antigen-binding domaincross-Fab fragment capable of specific binding to a second target is an antigen binding domain capable of specific binding to a tumor associated antigen.

105. The bispecific antibody of any one of claims 1 to 94, wherein the antigen-binding domaincross-Fab fragment capable of specific binding to a second target is an antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP).

~~116~~. The bispecific antibody of any one of claims 1 to ~~105~~, wherein the ~~antigen-binding domain~~cross-Fab fragment capable of specific binding to a second target comprises

(a) a heavy chain variable region (V_HFAP) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3, and a light chain variable region (V_LFAP) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6, or

(b) a heavy chain variable region (V_HFAP) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:9, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:10, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:11, and a light chain variable region (V_LFAP) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:12, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:13, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:14.

~~127~~. The bispecific antibody of any one of claims 1 to ~~116~~, wherein the ~~antigen-binding domain~~cross-Fab fragment capable of specific binding to a second target comprises

(a) a heavy chain variable region (V_HFAP) comprising an amino acid sequence of SEQ ID NO:7, and a light chain variable region (V_LFAP) comprising an amino acid sequence SEQ ID NO:8, or

(b) a heavy chain variable region (V_HFAP) comprising an amino acid sequence of SEQ ID NO:15, and a light chain variable region (V_LFAP) comprising an amino acid sequence of SEQ ID NO:16.

~~138~~. The bispecific antibody of any one of claims 1 to ~~127~~, wherein the ~~antigen-binding domain~~Fab fragment capable of specific binding to a first target is an antigen binding domain capable of specific binding to OX40.

~~149~~. The bispecific antibody of any one of claims 1 to ~~138~~, wherein the ~~antigen-binding domain~~Fab fragment capable of specific binding to a first target comprises

(a) a heavy chain variable region (V_HOX40) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:17, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:19, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:22, and a light chain variable region (V_LOX40) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:28, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:31, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:35, or

(b) a heavy chain variable region (V_HOX40) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:17, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:19, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:21, and a

light chain variable region (V_LOX40) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:28, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:31, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:34, or

(c) a heavy chain variable region (V_HOX40) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:17, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:19, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:23, and a light chain variable region (V_LOX40) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:28, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:31, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:36, or

(d) a heavy chain variable region (V_HOX40) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:17, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:19, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:24, and a light chain variable region (V_LOX40) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:28, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:31, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:37, or

(e) a heavy chain variable region (V_HOX40) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:18, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:20, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:25, and a light chain variable region (V_LOX40) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:29, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:32, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:38, or

(f) a heavy chain variable region (V_HOX40) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:18, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:20, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:26, and a light chain variable region (V_LOX40) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:29, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:32, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:38, or

(g) a heavy chain variable region (V_HOX40) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:18, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:20, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:27, and a light chain variable region (V_LOX40) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:30, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:33, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:39.

1510. The bispecific antibody of any one of claims 1 to 149, wherein the antigen-binding domainFab fragment capable of specific binding to a first target comprises

(a) a heavy chain variable region (V_HOX40) comprising an amino acid sequence of SEQ ID NO:40 and a light chain variable region (V_LOX40) comprising an amino acid sequence of

SEQ ID NO:41, or

(b) a heavy chain variable region (V_HOX40) comprising an amino acid sequence of SEQ ID NO:42 and a light chain variable region (V_LOX40) comprising an amino acid sequence of SEQ ID NO:43, or

5 (c) a heavy chain variable region (V_HOX40) comprising an amino acid sequence of SEQ ID NO:44 and a light chain variable region (V_LOX40) comprising an amino acid sequence of SEQ ID NO:45, or

(d) a heavy chain variable region (V_HOX40) comprising an amino acid sequence of SEQ ID NO:46 and a light chain variable region (V_LOX40) comprising an amino acid sequence of SEQ ID NO:47, or

(e) a heavy chain variable region (V_HOX40) comprising an amino acid sequence of SEQ ID NO:48 and a light chain variable region (V_LOX40) comprising an amino acid sequence of SEQ ID NO:49, or

10 (f) a heavy chain variable region (V_HOX40) comprising an amino acid sequence of SEQ ID NO:50 and a light chain variable region (V_LOX40) comprising an amino acid sequence of SEQ ID NO:51, or

(g) a heavy chain variable region (V_HOX40) comprising an amino acid sequence of SEQ ID NO:52 and a light chain variable region (V_LOX40) comprising an amino acid sequence of SEQ ID NO:53.

20 ~~1611~~. The bispecific antibody of any one of claims 1 to ~~1410~~, wherein the ~~antigen-binding domain~~Fab fragment capable of specific binding to a first target comprises

(a) a heavy chain variable region (V_HOX40) comprising an amino acid sequence of SEQ ID NO:40, and a light chain variable region (V_LOX40) comprising an amino acid sequence of SEQ ID NO:41.

25 ~~1712~~. The bispecific antibody of any one of claims 1 to ~~127~~, wherein the ~~antigen-binding domain~~Fab fragment capable of specific binding to a first target is an antigen binding domain capable of specific binding to 4-1BB.

~~1813~~. The bispecific antibody of any one of claims 1 to ~~12-7~~ or ~~1712~~, wherein the ~~antigen-binding domain~~Fab fragment capable of specific binding to a first target comprises a heavy chain variable region (V_H4-1BB) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:135, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:136, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:137, and a light chain variable region (V_L4-1BB) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:138, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:139, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:140.

5 ~~19~~14. The bispecific antibody of any one of claims 1 to ~~12~~7 or ~~17~~12 or ~~18~~13, wherein the ~~antigen-binding domain~~Fab fragment capable of specific binding to a first target comprises a heavy chain variable region (V_H4-1BB) comprising an amino acid sequence of SEQ ID NO:141, and a light chain variable region (V_L4-1BB) comprising an amino acid sequence of SEQ ID NO:142.

~~20~~15. The bispecific antibody of any one of claims 1 to ~~12~~7, wherein the ~~antigen-binding domain~~Fab fragment capable of specific binding to a first target is an antigen binding domain capable of specific binding to CD40.

10 ~~21~~16. The bispecific antibody of any one of claims 1 to ~~12~~7 or ~~20~~15, wherein the ~~antigen-binding domain~~Fab fragment capable of specific binding to a first target comprises a heavy chain variable region (V_HCD40) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:147, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:148, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:149, and a light chain variable region (V_LCD40) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:150, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:151, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:152.

20 ~~22~~17. The bispecific antibody of any one of claims 1 to ~~12~~7 or ~~20~~15 or ~~21~~16, wherein the ~~antigen-binding domain~~Fab fragment capable of specific binding to a first target comprises a heavy chain variable region (V_HCD40) comprising an amino acid sequence of SEQ ID NO:153, and a light chain variable region (V_LCD40) comprising an amino acid sequence of SEQ ID NO:154.

25 ~~23~~18. The bispecific antibody of any one of claims 1 to ~~12~~7 or ~~20~~15 or ~~21~~16, wherein the antigen binding domain capable of specific binding to a first target is an antigen binding domain capable of specific binding to a first target comprises
(i) a heavy chain variable region (V_HCD40) comprising an amino acid sequence selected from the group consisting of SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169 and SEQ ID NO:170, and a light chain variable region (V_LCD40) comprising the amino acid sequence selected from the group consisting of SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, and SEQ ID NO:174, or
30 (ii) a heavy chain variable region (V_HCD40) comprising an amino acid sequence selected from the group consisting of SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179 and SEQ ID NO:180, and a light chain variable region (V_LCD40) comprising the amino acid sequence selected from the group consisting of SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, and SEQ ID NO:184.

2419. Isolated nucleic acid encoding the bispecific antibody of any one of claims 1 to 2318.
2520. A vector or host cell comprising the nucleic acid of claim 2419.
- 5 2621. A method of producing a bispecific antibody culturing the host cell of claim 2520 under conditions suitable for the expression of the bispecific antibody.
2722. A pharmaceutical composition comprising the bispecific antibody of any one of claims 1 to 238 to 18 and a pharmaceutically acceptable excipient.
2823. The bispecific antibody of any one of claims 13 to 238 to 18 or the pharmaceutical composition of claim 2722 for use as medicament.
- 10 2924. The bispecific antibody of any one of claims 13 to 238 to 18 or the pharmaceutical composition of claim 2722 for use in treating cancer or infectious diseases.
3025. Use of the bispecific antibody of any one of claims 13 to 238 to 18 or the pharmaceutical composition of claim 2722 in the manufacture of a medicament for the treatment of infections or cancer.
- 15 3126. The pharmaceutical composition of claim 2722, the bispecific antibody or the pharmaceutical composition for use of claim 2823 or 2924, or the use of claim 3025, further comprising an additional therapeutic agent.
